Keldura Daily Open Keldura

Keldura Daily · Health & Medicine

FDA requires GLP-1 warnings about rare permanent vision loss

The FDA is requiring GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, to carry warnings about non-arteritic anterior ischemic optic neuropathy, or NAION. Merck announced FDA approval of PIMJETMI (pimicotinib), a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor when surgery may worsen function or cause severe harm. A surgeon in Mekele told NPR that a hospital treated casualties through nearly seven or eight days without electricity or cellular service as a ceasefire began collapsing in September.

The field note

3 sources · 3 items
  1. NAION occurs in roughly two to 10 people per 100,000 in the general population; that background figure is not a…
  2. Across 126 trials involving more than 130,000 patients, the FDA identified 15 probable cases: 10 among GLP-1 re…
  3. A separate FDA study found no increased risk compared with SGLT-2 diabetes drugs, but an increase compared with…
Story 012 sources

FDA requires GLP-1 warnings about rare permanent vision loss

The FDA is requiring GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, to carry warnings about non-arteritic anterior ischemic optic neuropathy, or NAION. The condition damages the optic nerve when its blood supply is restricted, potentially causing abrupt, permanent vision loss. [4][8] The agency's studies produced mixed results, supporting a warning about a potential risk rather than a settled causal relationship. [8]

Why it matters

People taking these medicines for diabetes or weight management face a new treatment consideration: an uncommon eye complication can have permanent consequences. The FDA advises clinicians to consider discontinuing a GLP-1 drug in patients who develop NAION unless treatment benefits clearly outweigh the risk—not to stop treatment in every patient. [8]

Key insights

  • NAION occurs in roughly two to 10 people per 100,000 in the general population; that background figure is not an estimate of the extra risk from GLP-1 treatment. [8]
  • Across 126 trials involving more than 130,000 patients, the FDA identified 15 probable cases: 10 among GLP-1 recipients and five among placebo recipients. Those counts alone do not establish a relative risk without the treatment-group denominators. [8]
  • A separate FDA study found no increased risk compared with SGLT-2 diabetes drugs, but an increase compared with DPP-4 drugs; diabetes and cardiovascular conditions also overlap with NAION risk factors. [8]
Story 021 source

FDA approves pimicotinib for patients facing harmful tumor surgery

Merck announced FDA approval of PIMJETMI (pimicotinib), a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor when surgery may worsen function or cause severe harm. In the Phase 3 MANEUVER trial, independently assessed tumor response at week 25 was 56% with the medicine versus 3% with placebo. [7] Merck also reported statistically significant improvements in movement, physical functioning and pain. [7]

Why it matters

For eligible adults, approval creates a treatment option when removing the tumor could itself cause substantial disability. The 53-percentage-point response difference is accompanied by reported improvements in pain and function—outcomes that affect daily life, not just tumor measurements. [7]

Key insights

  • The approval is restricted to symptomatic adults whose surgical resection may worsen functional limitation or cause severe morbidity; it is not a blanket indication for every patient with this tumor. [7]
  • Tumor responses were assessed by a blinded independent review committee, and the week-25 difference versus placebo was statistically significant. [7]
  • Among patients who responded at 25 weeks, 77% maintained clinical benefit after another 12 months of follow-up, according to Merck. That percentage describes responders, not everyone treated. [7]

Create your own daily briefing — start free. Keldura monitors the sources you choose and gives you a private, grounded daily digest with cited answers.

Create your own daily briefing — start free